Prelude Therapeutics Inc PRLD Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

May 25, 2023 (filed on May 26, 2023)

Insider Name:

Vaddi Krishna

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

900

Price:

$5.31
May 24, 2023 (filed on May 26, 2023)

Insider Name:

Vaddi Krishna

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,000

Price:

$5.01
May 24, 2023 (filed on May 25, 2023)

Insider Name:

Lim Bryant David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

2,400

Price:

$5.39
May 23, 2023 (filed on May 25, 2023)

Insider Name:

Chardonnet Laurent

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$5.50
May 23, 2023 (filed on May 25, 2023)

Insider Name:

Vaddi Krishna

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

11,856

Price:

$5.63
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Warrants to purchase Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,625,036

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Warrants to purchase Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

970,220

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Prelude Non-Voting Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,327,044

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Prelude Non-Voting Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

121,178

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

869,565

Price:

$5.75

Filings by filing date

May 25, 2023 (filed on May 26, 2023)

Insider Name:

Vaddi Krishna

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

900

Price:

$5.31
May 24, 2023 (filed on May 26, 2023)

Insider Name:

Vaddi Krishna

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

1,000

Price:

$5.01
May 24, 2023 (filed on May 25, 2023)

Insider Name:

Lim Bryant David

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

2,400

Price:

$5.39
May 23, 2023 (filed on May 25, 2023)

Insider Name:

Chardonnet Laurent

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

5,000

Price:

$5.50
May 23, 2023 (filed on May 25, 2023)

Insider Name:

Vaddi Krishna

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

11,856

Price:

$5.63
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Warrants to purchase Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,625,036

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Warrants to purchase Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

970,220

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Prelude Non-Voting Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

1,327,044

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Baker Bros. Advisors Lp

Ownership Type:

Indirect Ownership

Securities:

Prelude Non-Voting Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

121,178

Price:

$5.75
May 22, 2023 (filed on May 24, 2023)

Insider Name:

Orbimed Advisors Llc

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

869,565

Price:

$5.75

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	200 Powder Mill Road WILMINGTON DE 19803
Tel:	N/A
Website:	https://preludetx.com
IR:	See website

Key People

Jane Huang President, Chief Medical Officer	Krishna Vaddi Chief Executive Officer, Founder, Director	Laurent Chardonnet Chief Financial Officer
Andrew P. Combs Executive Vice President, Head of Chemistry	Peggy A. Scherle Chief Scientific Officer	Bryant D. Lim Chief Legal Officer, Company Secretary

Business Overview

Prelude Therapeutics Inc. is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. The Company's product candidates include PRT1419, PRT2527, PRT3789, and PRT3645. PRT1419 is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527 is a potent and highly selective CDK9 inhibitor. PRT2527 treatment demonstrated robust efficacy in both hematological malignancies and solid tumor models with MYC. PRT3645 is a next-generation CDK4/6 inhibitor. PRT3789 is an IV-administered SMARCA2 degrader. Its pipeline consists of multiple distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders.

Financial Overview

For the three months ended 31 March 2023, Prelude Therapeutics Inc revenues was not reported. Net loss decreased 6% to $27.7M. Lower net loss reflects Research and development decrease of 4% to $18.8M (expense), Other income, net increase of 70% to $1.4M (income), Stock-based Compensation in SGA decrease of 10% to $3.3M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.63 to -$0.58.

Employees:	122 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$126.20M as of Mar 31, 2023
Annual revenue (TTM):	$0.00M as of Mar 31, 2023
EBITDA (TTM):	-$121.07M as of Mar 31, 2023
Net annual income (TTM):	-$113.69M as of Mar 31, 2023
Free cash flow (TTM):	-$94.85M as of Mar 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	100,368,004 as of May 18, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization